CD19 / CD20 / Firefly Luciferase CHO Cell Line
Clonal stable CHO cell line constitutively expressing full length human CD19 protein (also known as CVID3, Genbank accession #NM_001770) and human CD20 protein (also known as MS4A1 and FMC7, Genbank accession #NM_021950). This cell line was derived from our CHO-K1 Luciferase cells (BPS Bioscience, #79725), therefore it also constitutively expresses the firefly luciferase reporter. Surface expression of CD19 and CD20 were confirmed by flow cytometry.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Materials Required for Cell Culture
| Name | Ordering Information |
| Thaw Medium 3 | BPS Bioscience #60186 |
| Growth Medium 3K | BPS Bioscience #78041 |
Materials Required for Cellular Assay
| Name | Ordering Information |
| ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
| 96-well tissue culture-treated white clear-bottom assay plate |
|
| Luminometer |
The cell line has been screened using the MycoAlert™ Mycoplasma Detection kit (Lonza, #LT07-218) to confirm the absence of Mycoplasma species.
B-lymphocyte antigen CD19 (Cluster of Differentiation 19), also known as B-Lymphocyte Surface Antigen B4 and CVID3, is a transmembrane protein expressed in follicular dendritic cells and all B lineage cells except plasma cells. CD19 plays two major roles in human B cells. It acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane and it works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. Due to its presence on all B cells, it is a biomarker for B lymphocyte development and lymphoma diagnosis and can be used as a target for leukemia immunotherapies. CD19-targeted therapies based on T cells that express CD19-specific chimeric antigen receptors (CARs) have been utilized for their antitumor abilities in patients with CD19+ lymphoma and leukemia, such as Non-Hodgkins Lymphoma (NHL), CLL and ALL.
CD20 (MS4A1) is a glycosylated phosphoprotein expressed on the cell surface of B cells. Although the functional significance of CD20 is not clear, and CD20 has no known ligands, CD20 has been shown to regulate intracellular calcium levels. CD20 is a highly attractive target antigen for immunotherapy because it is expressed in more than 90% of patients with B-cell lymphoma. First approved in 1997, Rituximab (Rituxan) is a chimeric monoclonal antibody targeting CD20 and has been classified by the World Health Organization as an “Essential Medicine”. Since then, additional monoclonal antibodies against CD20 have been approved or are being tested in clinical trials for the treatment of multiple sclerosis (MS), chronic lymphocytic leukemia (CLL), follicular lymphoma, diffuse large B cell lymphoma (DLBCL), rheumatoid arthritis, non-Hodgkin’s lymphoma, systemic lupus erythematosus, and myalgic encephalomyelitis (chronic fatigue syndrome). Additionally, more recently, anti-CD20-CD19 bispecific CAR-T cells have been developed to address concerns over potential relapse.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.